Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer

Autor: Vriens, B.E., Aarts, M.J., Vries, B. de, Gastel, S.M. van, Wals, J., Smilde, T.J., Warmerdam, L.J. van, Boer, M. de, Spronsen, D.J. van, Borm, G.F., Tjan-Heijnen, V.C., Stienen, J.J.C., Hermens, R.P.M.G., Wennekes, L., Schans, S.A. van de, Dekker, H.M., Blijlevens, N.M.A., Maazen, R.W.M. van der, Adang, E.M.M., Krieken, J.H.J.M. van, Ottevanger, P.B.
Přispěvatelé: Promovendi ODB, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Pathologie, RS: GROW - School for Oncology and Reproduction
Rok vydání: 2013
Předmět:
Oncology
Invasive mycoses and compromised host Translational research [N4i 2]
Adult
Cancer Research
medicine.medical_specialty
Cyclophosphamide
Adolescent
medicine.medical_treatment
Quality of nursing and allied health care [NCEBP 6]
Breast Neoplasms
Aetiology
screening and detection [ONCOL 5]
Docetaxel
Neoadjuvant chemotherapy
Disease-Free Survival
Drug Administration Schedule
Young Adult
Breast cancer
Translational research [ONCOL 3]
Internal medicine
Evaluation of complex medical interventionsQuality of Care [NCEBP 2]
Antineoplastic Combined Chemotherapy Protocols
Medicine
Humans
Survival rate
Neoadjuvant therapy
Aged
Chemotherapy
business.industry
Cumulative dose
Effective primary care and public health [NCEBP 7]
Middle Aged
medicine.disease
Translational research Tissue engineering and pathology [ONCOL 3]
Neoadjuvant Therapy
Survival Rate
Chemotherapy
Adjuvant
Doxorubicin
Quality of hospital and integrated care Quality of Care [NCEBP 4]
Female
Taxoids
business
Quality of hospital and integrated care [NCEBP 4]
Febrile neutropenia
medicine.drug
Quality of Care Quality of hospital and integrated care [ONCOL 4]
Zdroj: European Journal of Cancer, 49, 15, pp. 3102-10
European Journal of Cancer, 49, 3102-10
European Journal of Cancer, 49(15), 3102-3110. ELSEVIER SCI LTD
ISSN: 1879-0852
0959-8049
Popis: Contains fulltext : 127295.pdf (Publisher’s version ) (Closed access) Abstract BACKGROUND: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients. PATIENTS AND METHODS: Women with newly diagnosed breast cancer were randomly assigned to neoadjuvant chemotherapy of four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC 60/600 - T 100mg/m(2)) or six cycles of TAC (75/50/500mg/m(2)) every 3 weeks. The primary endpoint was the pathologic complete response (pCR) rate, defined as no invasive tumour present in the breast. RESULTS: In total, 201 patients were included. Baseline characteristics were well balanced. AC-T resulted in pCR in 21% and TAC in 16% of patients (odds ratio 1.44 (95% confidence interval (CI) 0.67-3.10). AC-T without primary granulocyte-colony stimulating factor (G-CSF) prophylaxis was associated with more febrile neutropenia compared to TAC with primary G-CSF prophylaxis (23% versus 9%), and with more grade 3/4 sensory neuropathy (5% versus 0%). CONCLUSIONS: With a higher cumulative dose for the concurrent arm, no differences were observed between the two treatment arms with respect to pCR rate. The differential toxicity profile could partly be explained by different use of primary G-CSF prophylaxis. Copyright © 2013 Elsevier Ltd. All rights reserved. KEYWORDS: Breast cancer, Cyclophosphamide, Docetaxel, Doxorubicin, Neoadjuvant chemotherapy
Databáze: OpenAIRE
Externí odkaz: